Advertisement

Topics

Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients

07:02 EDT 11 Sep 2017 | FinanzNachrichten

Data from Ongoing Phase 2 Clinical Trial Shows Favorable PK and Evidence of RARa Target Engagement in Patients with Proprietary RARA or IRF8 Biomarkers Company Expects to Present Initial Phase 2 C...

Original Article: Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients

NEXT ARTICLE

More From BioPortfolio on "Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...